Myriad Genetics, Inc. announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise?? MRD Test to detect and monitor ctDNA in patients. The interim results - first shared at the 2025 ASCO Annual Meeting by Tadayoshi Hashimoto, MD, PhD of the NCCHE - achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood.
Key findings include: Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested. The SCRUM-MONSTAR-SCREEN-3 study explores how multi-omic profiling, including MRD, can be used to develop more personalized treatment and therapeutic strategies in three study cohorts. Approximately 1,200 patients across more than 20 cancer types are undergoing MRD monitoring via Precise MRD as part of the study.
The Precise MRD test can be used to monitor ctDNA levels throughout a cancer patient's clinical care, starting immediately after diagnosis and continuing through treatment. Precise MRD is available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators. Myriad continues to develop its Precise MRD assay to meet the needs of patients with cancer, academic partners, and biopharma companies.
The test is currently being evaluated in several high-impact studies and is performed at the company's laboratory facility in Salt Lake City.
